FOAMIX PHARMACEUT.IS -,16 Aktie

Foamix has a strong in-house pipeline of drugs for dermatologic, ophthalmologic and gynecologic indications. The Company’s lead product under development is the first-in-class Topical Minocycline Foam addressing large markets in dermatology and ophthalmology. Minocycline foam demonstrated high efficacy and favorable safety in two phase II clinical studies in Acne and Impetigo patients. Foamix Ltd. is a clinical-stage, privately held specialty pharmaceutical company, focused on the development of proprietary topical foams and OilGel™ products for dermatology, gynecology, wounds and burns as well as ophthalmic disorders.